FMS vs. DVA, SHC, PGNY, SRPT, UTHR, EXAS, SNN, TECH, RGEN, and NTRA
Should you be buying Fresenius Medical Care stock or one of its competitors? The main competitors of Fresenius Medical Care include DaVita (DVA), Sotera Health (SHC), Progyny (PGNY), Sarepta Therapeutics (SRPT), United Therapeutics (UTHR), Exact Sciences (EXAS), Smith & Nephew (SNN), Bio-Techne (TECH), Repligen (RGEN), and Natera (NTRA). These companies are all part of the "medical" sector.
Fresenius Medical Care (NYSE:FMS) and DaVita (NYSE:DVA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, earnings, dividends, analyst recommendations, community ranking, risk, profitability, media sentiment and institutional ownership.
DaVita has lower revenue, but higher earnings than Fresenius Medical Care. DaVita is trading at a lower price-to-earnings ratio than Fresenius Medical Care, indicating that it is currently the more affordable of the two stocks.
DaVita has a net margin of 5.70% compared to Fresenius Medical Care's net margin of 2.56%. DaVita's return on equity of 64.42% beat Fresenius Medical Care's return on equity.
Fresenius Medical Care has a beta of 1, suggesting that its share price has a similar volatility profile to the S&P 500.Comparatively, DaVita has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.
Fresenius Medical Care presently has a consensus price target of $24.00, suggesting a potential upside of 24.45%. DaVita has a consensus price target of $118.50, suggesting a potential downside of 14.19%. Given Fresenius Medical Care's higher probable upside, equities research analysts clearly believe Fresenius Medical Care is more favorable than DaVita.
8.3% of Fresenius Medical Care shares are owned by institutional investors. Comparatively, 90.1% of DaVita shares are owned by institutional investors. 1.4% of DaVita shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
In the previous week, DaVita had 3 more articles in the media than Fresenius Medical Care. MarketBeat recorded 6 mentions for DaVita and 3 mentions for Fresenius Medical Care. DaVita's average media sentiment score of 1.36 beat Fresenius Medical Care's score of 0.48 indicating that DaVita is being referred to more favorably in the news media.
DaVita received 88 more outperform votes than Fresenius Medical Care when rated by MarketBeat users. Likewise, 61.66% of users gave DaVita an outperform vote while only 53.75% of users gave Fresenius Medical Care an outperform vote.
Summary
DaVita beats Fresenius Medical Care on 14 of the 18 factors compared between the two stocks.
Get Fresenius Medical Care News Delivered to You Automatically
Sign up to receive the latest news and ratings for FMS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Fresenius Medical Care Competitors List
Related Companies and Tools